Keryx Falls on Questions About Zerenex Market Exclusivity

Keryx Pharmaceuticals shares fell 22 percent to $7.11 Friday after an independent research firm raised questions about the company’s ability to convince the FDA to grant new chemical entity status to its experimental iron-based phosphate binder Zerenex (ferric citrate).
The Street